New perspectives for targeting RAF kinase in human cancer

Cited by (409)

Items 301–400 of 409

1. The Role of the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Cancer
   Sajedeh Lotfaliansaremi, Michael L. Sabio, Stephen Comwell, Peter P. Tolias · 2020 · Medical Research Archives
2. Latent allosteric control of protein interactions by ATP-competitive kinase inhibitors
   David Vaisar, Natalie G. Ahn · 2024 · Current Opinion in Structural Biology
3. A two-pronged attack
   Joshua J. Feng, Chao Zhang · 2020 · Nature Chemical Biology
4. Multiomics Identifies Potential Molecular Profiles Associated With Outcomes After BRAF-Targeted Therapy in Patients With BRAF V600E-Mutated Advanced Solid Tumors
   Martina Amnitzbøll Eriksen, Ann Kristin Hansen, Annelaura Bach Nielsen, Filip Oskar Mundt, Matthias Mann, Ulrik Lassen, Lise Barlebo Ahlborn, Martin Højgaard, Iben Spanggaard, Camilla Qvortrup et al. · 2025 · JCO Precision Oncology
5. The BRAF ‐specific region suppresses cysteine‐rich domain–lipid interaction independently of canonical autoinhibition by the 14‐3‐3 dimer
   Vasili Revazishvili, Alexia Morales, Bryn I. Baxter, J. Norman Grim, Ani Chakhrakia, Andres Jimenez Salinas, Kesaria Tevdorashvili, Angelica M. Riestra, Young Kwang Lee · 2025 · Protein Science
6. MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC
   Chushu Li, Shouyan Deng, Minxian Zhuang, Tihui Li, Liying Lin, Linfu Zheng, Kun Lin, Dazhou Li, Fenglin Chen · 2026 · Oncogene
7. Targeting KRAS for cancer therapy
   Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos · 2026 · British Journal of Pharmacology
8. [Research Progress of BRAF Fusion in Non-small Cell Lung Cancer].
   Ping Xiao, Diansheng Zhong · 2023 · PubMed Central
9. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling
   Benny Johnson, Van Karlyle Morris, Xuemei Wang, Arvind N. Dasari, Kanwal P. S. Raghav, John Paul Shen, Michael S. Lee, Ryan W. Huey, Christine Megerdichian Parseghian, Jason A. Willis et al. · 2024 · Cancers
10. The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer
    Barbara L. Melosky, Rosalyn Anne Juergens, Shantanu Otto Banerji, Adrian G. Sacher, Paul Wheatley‐Price, Stephanie Leann Snow, Ming‐Sound Tsao, Natasha B. Leighl, Ilidio Martins, Parneet Kaur Cheema et al. · 2025 · Therapeutic Advances in Medical Oncology
11. Genomic Alterations in Langerhans Cell Histiocytosis
    Nitya Gulati, Erin C. Peckham‐Gregory, Donald Williams Parsons, Carl E. Allen · 2025 · Hematology/Oncology Clinics of North America
12. A multi-omic analysis reveals a predictive value of tertiary lymphoid structures in improving the prognosis of colorectal cancer patients with BRAF mutation
    Chao Qin, Shumin Cheng, Jingyun Ma, Lujing Li, Yun Leng, Lei Zheng, Huiying Chen, Hui Mo, Shi Li, Yuhong Liang et al. · 2025 · Frontiers in Immunology
13. Review of Phase II Basket Trials for Precision Medicine
    Yeonhee Park · 2019 · Annals of Biostatistics & Biometric Applications
14. La résistance aux inhibiteurs de BRAF
    Cylia Dahmani, Eulalie Corre, Sarah Dandou, Alain Mangé, Ovidiu Radulescu, Peter J. P. Coopman, Pierre Cuq, Romain M. Larive · 2022 · médecine/sciences
15. Ensemble Pharmacophore Meets Molecular Docking: A Novel Screening Approach for the Identification of B-Raf Kinase Inhibitors
    Muni Sireesha Sunkara, Vinutha Kuchana, JYOTHI VEMURI, Dipankar Bhowmik · 2022 · Trends in Sciences
16. Targeting SHP2 Reverses BRAF Inhibitor Tolerance in Anaplastic Thyroid Carcinoma
    Tao Tang, Jie Zhou, Li-Xin Zhang, Gang Yang, Weinan Li, Zhu Jian-Jiao, Yong-fu Xiong, Jingdong Li · 2023 · Anti-Cancer Agents in Medicinal Chemistry
17. Kinase perturbations redirect mitochondrial function in cancer
    Omar Torres‐Quesada, Sophie Luise Strich, Eduard Stefan · 2022 · PubMed
18. RAF conformational autoinhibition and 14-3-3 proteins promote paradoxical activation
    Gaurav Mendiratta, Kodye Abbott, Yao-Cheng Li, Jingting Yu, Jianfeng Huang, Maxim Nikolaievich Shokhirev, Thomas McFall, Geoffrey M. Wahl, Edward C. Stites · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
19. Aberrant Signaling Pathways in Cancer
    Luca Grumolato, Stuart A. Aaronson · 2022 · Wiley eBooks
20. Protomer Selectivity of RAF Inhibitors Within the RAS/RAF Signalosome
    James D. Vasta, Ani Michaud, Chad Zimprich, Morgan Thomas, Jennifer Wilkinson, J. Aaron Crapster, Matthew B. Robers · 2022 · Research Square
21. Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors
    Joseph Clayton, Aarion Romany, Evangelia Matenoglou, Evripidis Gavathiotis, Poulikos I. Poulikakos, Jana Shen · 2024 · eLife
22. Characterization and inhibitor sensitivity of ARAF, BRAF, and CRAF complexes
    Emre Tkacik, Dong Man Jang, Kayla Boxer, Byung Hak Ha, Michael J. Eck · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
23. In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation
    Jiani Chen, Jingwen Zhai, Mingming Li, Shiyi Liu, Xiaobin Gong, Hongyu Yu, Hua Wei, Wansheng Chen · 2023 · Cancer Cell International
24. Illuminating DEPDC1B in Multi-pronged Regulation of Tumor Progression
    Howard E. Boudreau, Jennifer Robinson, Usha N. Kasid · 2023 · Methods in molecular biology
25. A Method to Conditionally Measure Target Engagement at Intracellular RAS and RAF Complexes
    James D. Vasta, Ani Michaud, J. Aaron Crapster, Matthew B. Robers · 2024 · Methods in molecular biology
26. The paradoxical activity of BRAF inhibitors: potential use in wound healing
    Sonali Karhana, Mohd Samim, Nidhi, Mohd Ashif Khan · 2025 · Archives of Dermatological Research
27. Mathematical modeling suggests 14-3-3 proteins modulate RAF paradoxical activation
    Gaurav Mendiratta, Kodye L. Abbott, Yaocheng Li, Jingting Yu, Peter Carlip, Melinda M. Tong, Jianfeng Huang, Maxim Nikolaievich Shokhirev, Thomas B. McFall, Geoffrey M. Wahl et al. · 2025 · PLoS Computational Biology
28. TGM2 regulated by transcription factor NR3C1 drives p38 MAPK-mediated tumor progression and immune evasion in lung squamous cell carcinoma
    Chunlong Lin, Shangfu Li, Yi Liang, Huiling Zhou, Zhiyi Xiao, Zhuo Yang, Qingping Chen, Xiangyang Peng, Kanao Li, Qing Wang et al. · 2025 · Frontiers in Immunology
29. Using Optical Tweezers to Dissect Allosteric Communication Networks in Protein Kinases
    Yuxin Hao, Rodrigo A. Maillard · 2022 · Methods in molecular biology
30. Wild-type C-Raf gene dosage and dimerization drive prostate cancer metastasis
    Lisa H. Ta, Brandon L. Tsai, Weixian Deng, Jihui Sha, Grigor Varuzhanyan, Wendy Tran, James Akira Wohlschlegel, Janai R. Carr, Owen N. Witte · 2023 · iScience
31. Thioxo-tetrahydro-pyrimidin-benzenesulfonamide hybrids as potential BRAFV600E inhibitors: experimental, computational and biological evaluations
    Ankit Kumar Singh, Adarsh M Kumar, Kristina Kraljić, Prateek Pathak, Amita Verma, Jurica Novak, Pradeep Kumar · 2025 · Journal of Molecular Structure
32. Oncolytic reovirus shows potentially anticancer effect against CT26 cell lines
    Abouzar Babaei, Hoorieh Soleimanjahi, Ehsan Arefian · 2019
33. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
    Xinyuan Tong, Ayushi S. Patel, Eejung Kim, Hongjun Li, Yueqing Chen, Shuai Li, Shengwu Liu, Julien Dilly, Kevin S. Kapner, Yun Xue et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
34. Kinases in motion: impact of protein and small molecule interactions on kinase conformations
    Valentina Kugler, Selina Schwaighofer, Andreas Feichtner, Florian Enzler, Jakob Fleischmann, Sophie Luise Strich, Sarah Schwarz, Rebecca Wilson, Philipp Tschaikner, Jakob Troppmair et al. · 2024 · eLife
35. Mechanism of Dimer Selectivity and Binding Cooperativity of BRAF Inhibitors
    Joseph Clayton, Aarion Romany, Evangelia Matenoglou, Evripidis Gavathiotis, Poulikos I. Poulikakos, Jana Shen · 2025 · eLife
36. Blocking KRAS Signaling for the Treatment of Lung Cancer: Mission Possible?
    Yoshitsugu Horio · 2018 · Haigan
37. Development of split luciferase complementation probes sensing KRAS/effector interaction
    Kyoko Miyamoto, Kanako Ishihara, Masaaki Sawa · 2019 · Translational and Regulatory Sciences
38. Pharmaceutical applications of organofluorine compounds
    V. Prakash Reddy · 2020 · Elsevier eBooks
39. US FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy
    Mingfeng Yu, Solomon Tadesse, Shudong Wang · 2021 · Wiley eBooks
40. 9335 槍ヶ岳山荘の建設工程に関する復原的考察(日本近代:建築技術・史料,建築歴史・意匠)
    成央 梅干野, 啓 田村, 俊和 土本 · 2010 · 学術講演梗概集. F-2, 建築歴史・意匠
41. Faculty Opinions recommendation of Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes.
    Thomas A. Leonard · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
42. Faculty Opinions recommendation of MEK drives BRAF activation through allosteric control of KSR proteins.
    Thomas A. Leonard · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
43. Targeted Therapy
    Maurizio D’Incalci, Elena Monti, Lorena Incorvaia, Marta Castiglia, Antonio Dello Russo, Viviana Bazan · 2021 · UNIPA Springer series
44. Data from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
    Meagan B. Ryan, Ferran Fece de la Cruz, Sarah Phat, David T. Myers, Edmond Wong, Heather A. Shahzade, Catriona B. Hong, Ryan Bruce Corcoran · 2023
45. Data from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
    Meagan B. Ryan, Ferran Fece de la Cruz, Sarah Phat, David T. Myers, Edmond Wong, Heather A. Shahzade, Catriona B. Hong, Ryan Bruce Corcoran · 2023
46. Up-regulation of NGEF by ERK/AP1 signaling pathway in BRAFV600E-mutant thyroid cancer promotes cancer metastasis
    Zhao Fu, Ye Wang, Congjun Wang, Zhu Yu, Weijia Huang, Kaitian Zheng, Shengyu Wang, Jian Yang, Junqiang Chen · 2023 · Research Square
47. Off-targets of BRAF inhibitors disrupt endothelial signaling and differentially affect vascular barrier function
    Sophie Bromberger, Yuliia Zadorozhna, Julia Maria Ressler, Silvio Holzner, Arkadiusz Nawrocki, Nina Zila, Alexander Springer, Martin R. Larsen, Klaudia Schossleitner · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
48. Raf protomers: Drug binding preferences in living cells
    Kevin N. Dalby · 2023 · Cell chemical biology
49. DEVELOPMENT OF TARGETED DRUG COMBINATIONS BLOCKING MULTI-DRIVER ONCOGENESIS
    Alexander Yonchak · 2023 · Digital Commons - URI (University of Rhode Island)
50. Kinases in motion: impact of protein and small molecule interactions on kinase conformations
    Valentina Kugler, Selina Schwaighofer, Andreas Feichtner, Florian Enzler, Jakob Fleischmann, Sophie Luise Strich, Sarah Schwarz, Rebecca Wilson, Philipp Tschaikner, Jakob Troppmair et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
51. Kinases in motion: impact of protein and small molecule interactions on kinase conformations
    Valentina Kugler, Selina Schwaighofer, Andreas Feichtner, Florian Enzler, Jakob Fleischmann, Sophie Luise Strich, Sarah Schwarz, Rebecca Wilson, Philipp Tschaikner, Jakob Troppmair et al. · 2024 · eLife
52. Reviewer #2 (Public Review): Kinases in motion: impact of protein and small molecule interactions on kinase conformations
    2024 · eLife
53. Mechanism of Dimer Selectivity and Binding Cooperativity of BRAF inhibitors
    Joseph Clayton, Aarion Romany, Evangelia Matenoglou, Evripidis Gavathiotis, Poulikos I. Poulikakos, Jana Shen · 2024 · eLife
54. Mechanism of Dimer Selectivity and Binding Cooperativity of BRAF Inhibitors
    Joseph Clayton, Aarion Romany, Evangelia Matenoglou, Evripidis Gavathiotis, Poulikos I. Poulikakos, Jana Shen · 2024 · eLife
55. MDSGCN: Predicting Multiple Types of Mutation-Drug Association Through Signed Graph Convolution Network
    Haisong Feng, Xiaosong Wang, Fan Lin · 2025 · IEEE Transactions on Computational Biology and Bioinformatics
56. Prediction and Validation of Novel BRAF Inhibitor as a Potential Drug Candidate for the Treatment of Colorectal Cancer
    Amrutha Krishnan K, Sudha George Valavi, Amitha Joy · 2025 · Current Topics in Medicinal Chemistry
57. Landscape of BRAF transcript variants in human cancer
    Maurizio Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D’Aurizio, Laura Poliseno · 2025 · Molecular Oncology
58. Up-regulation of NGEF via the BRAFV600E /ERK/AP1 pathway enhances invasion and migration abilities of BRAFV600E-mutant thyroid cancer
    Zhao Fu, Ye Wang, Congjun Wang, Zhu Yu, Junqiang Chen · 2025 · Biochemistry and Biophysics Reports
59. Quantitative Membrane Binding Assays Reveal an Inhibitory Role for the BRAF-Specific Region in CRD and Lipid Interaction
    Vasili Revazishvili, Alexia Morales, Bryn Baxter, Julian Grim, Ani Chakhrakia, Andres Jimenez Salinas, Angelica M. Riestra, Young Kwang Lee · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
60. Forebrain-Specific B-raf Deficiency Reduces NMDA Current and Enhances Small-Conductance Ca2+-Activated K+ (SK) Current
    Cornelia Ruxanda, Christian Alzheimer, Fang Zheng · 2025 · International Journal of Molecular Sciences
61. mTOR inhibition enhances the antitumor efficacy of RAF dimer-MEK blockade by inhibiting the ATF4-MTHFD2 pathway
    Sonia Victoria Del Rincon, Feiyang Cai, Fan Huang, Christophe Gonçalves, Harinee Srikannan, Natascha Gagnon, Elizabeth M. Guettler, Léa Mukeba-Harchies, Jennifer Maxwell, Jie Su et al. · 2025 · Research Square
62. In vitro reconstitutions suggest a general model for paradoxical activation of ARAF, BRAF, and CRAF by diverse RAF inhibitor types that does not rely on negative allostery
    Emre Tkacik, Dong Man Jang, Kayla Boxer, Byung Hak Ha, Michael J. Eck · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
63. Additional file 3 of Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase
    Lino Rohrer, Corinna Spohr, Carina Beha, Ricarda Griffin, Braun, Sandra, Sebastian Halbach, Tilman Brummer · 2023 · Figshare
64. Additional file 2 of In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation
    Chen, Jiani, Jingwen Zhai, Li, Mingming, Shiyi Liu, Gong, Xiaobin, Yu, Hongyu, Wei, Hua, Chen, Wansheng · 2024 · Figshare
65. Additional file 1 of Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase
    Lino Rohrer, Corinna Spohr, Carina Beha, Ricarda Griffin, Braun, Sandra, Sebastian Halbach, Tilman Brummer · 2023 · Figshare
66. Additional file 1 of Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
    Wu, Qing, Qian, Wei, Xiaoli Sun, Shaojie Jiang · 2022 · Figshare
67. Additional file 1 of Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
    Muhammad Elnaggar, Sarita Agte, Restrepo, Paula, Meghana Ram, David T. Melnekoff, Adamopoulos, Christos, Mark M. Stevens, Katerina Kappes, Violetta V. Leshchenko, Verina, Daniel et al. · 2022 · Figshare
68. Additional file 1 of In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation
    Chen, Jiani, Jingwen Zhai, Li, Mingming, Shiyi Liu, Gong, Xiaobin, Yu, Hongyu, Wei, Hua, Chen, Wansheng · 2024 · Figshare
69. Additional file 4 of Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase
    Lino Rohrer, Corinna Spohr, Carina Beha, Ricarda Griffin, Braun, Sandra, Sebastian Halbach, Tilman Brummer · 2023 · Figshare
70. Additional file 2 of Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase
    Lino Rohrer, Corinna Spohr, Carina Beha, Ricarda Griffin, Braun, Sandra, Sebastian Halbach, Tilman Brummer · 2023 · Figshare
71. Outcomes with frontline immune checkpoint inhibitors among individuals with BRAF-mutant non-small cell lung cancer
    Julian Andres Marin-Acevedo, Ram Thapa, Sudeepthi V. Bandikatla, Dung-Tsa Chen, J. Kevin Hicks, Jhanelle Gray, Sonam Puri · 2025 · Frontiers in Oncology
72. A molecular glue halts RAS–MAPK signaling
    Evripidis Gavathiotis · 2026 · Nature Cancer
73. GLUD1 supports ovarian cancer progression by counteracting anoikis via ARAF/MEK/ERK signaling
    Huolun Feng, Yanzhen Chen, Geyan Wu, Zhentao Zhang, Hongkun Lai, Changnian Yang, S Zhang, Yu-Fang Lin, Yingqi Liu, Haiyan Ye et al. · 2026 · npj Precision Oncology
74. Development and Preliminary Evaluations of a Novel 18 F-Labeled Tracer for Detection of BRAF V600E Mutant Status in Animal Models of Melanoma
    Yiming Guo, Zi Wang, Yingfang He, Wanru Zhuang, Jun Qian, Zijing Li, Chen‐Tian Shen, Junbin Han · 2026 · Molecular Pharmaceutics
75. Associations of Tumor Somatic Mutations and Genetic Alterations with Survival Outcomes in Melanoma Patients Treated with Ipilimumab
    Mohammad Ali Khaksar, Islam Eljilany, Ibrahim Yassine, Xiaoqing Yu, Jamie K. Teer, Jose Ramon Conejo-Garcia, Maureen Lyons, William A. LaFramboise, Ahmad A. Tarhini · 2026 · Journal of Clinical Medicine
76. In vitro reconstitutions suggest a general model for paradoxical activation of ARAF, BRAF, and CRAF by diverse RAF inhibitor types that does not rely on negative allostery
    Emre Tkacik, Dong Man Jang, Kayla Boxer, Byung Hak Ha, Michael J. Eck · 2026 · eLife
77. In vitro reconstitutions suggest a general model for paradoxical activation of ARAF, BRAF, and CRAF by diverse RAF inhibitor types that does not rely on negative allostery
    Emre Tkacik, Dong Man Jang, Kayla Boxer, Byung Hak Ha, Michael J. Eck · 2026 · eLife
78. Mécanismes de résistance aux thérapies ciblées du mélanome : implication du facteur de transcription Aryl hydrocarbon Receptor
    Nina Tardif · 2019 · theses.fr (ABES)
79. MiR-4510 suppresses hepatocellular carcinoma development through RAF1 targeting and MAPK/ERK signaling inhibition
    Amani Ghousein · 2018 · theses.fr (ABES)
80. Rôle de la kinase ARAF dans le mélanome cutané muté NRAS
    Charlène Estrada · 2020 · theses.fr (ABES)
81. Thérapies ciblées dans le mélanome : mécanismes impliqués dans les effets paradoxaux, les résistances et évaluation de nouvelles combinaisons
    Amelie M. Boespflug · 2018 · theses.fr (ABES)
82. Machine learning approaches for drug virtual screening
    Benoît Playe · 2019 · theses.fr (ABES)
83. Identification et modulation des voies moléculaires impliquées dans l’agressivité du mélanome cutané
    Arthur Gautron · 2019 · theses.fr (ABES)
84. Mécanismes et implications thérapeutiques de l'hypermutation dans les gliomes
    Mehdi Touat · 2020 · theses.fr (ABES)
85. Caractérisation des cellules tumorales portant la mutation BRAFV600E dans le cancer colorectal, CRC
    Olivia Villeronce · 2020
86. Etude des anomalies du métabolisme énergétique associées au syndrome de Noonan
    Sophie Branka · 2019 · theses.fr (ABES)
87. Une nouvelle stratégie thérapeutique pour prolonger la réponse du cancer bronchique aux inhibiteurs d’EGFR en prévenant l’émergence des cellules résistantes
    Lisa Brunet · 2021 · theses.fr (ABES)
88. Conception, synthèse et évaluation biologique de nouveaux inhibiteurs fluorescents et non fluorescents de la protéine kinase BRAF
    Otmane Bourzikat · 2023
89. Caractérisation du remodelage de l’organisation du collagène de type I en matrice 3D au cours du vieillissement par micro-imageries optiques : impact sur les propriétés mécaniques et la réponse du mélanome BRAFV600E aux thérapies ciblées
    Laetitia Florent · 2024 · theses.fr (ABES)
90. Unlocking drug sensitivity in KRAS
    MingCong LI, YueSong ZHOU, Tai Dong Qiao, QingLin BAI, Chuanchuan Li · 2026 · Scientia Sinica Vitae
91. Cryo-EM structure and biochemical characterization of a BRAF/CRAF heterodimer: Negative charge in the NtA motif is not required for RAF activation
    Byung Hak Ha, Emre Tkacik, Dimitrios Gazgalis, Hyelim Kang, Dong Man Jang, Sayan Chakraborty, Hyesung Jeon, Michael J. Eck · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
92. Design and Synthesis of Pyrimidino[4,5‐ d ]Pyrimidine‐Based Compounds as Potent B‐RAF V600E Inhibitors
    Eleftheria A. Georgiou, Kalliopi Christopoulou, Amalia D. Kalampaliki, Aikaterini F. Giannopoulou, Eleftheria Chatziorfanou, Vivi Bafiti, Andreas Krämer, Athanasios Papakyriakou, Dimitrios J. Stravopodis, Stefan Knapp et al. · 2026 · ChemMedChem
93. Phytochemical profiling and antimelanoma activity of Balinese mace oleoresin with computational insights into BRAF inhibition
    Rini Retnosari, I Wayan Mudianta, Galih Satrio Putra, Riri Jonuarti, Jalifah Latip · 2026 · Natural Product Research
94. Drugging ERK1/2 in Cancer: A Glimpse of Small‐Molecule Inhibitors
    Zhu Peng, Yuqi Fu, Yanmei Chen, Bo Fan, Bo Liu · 2026 · Medicinal Research Reviews
95. Targeting BRAF dimerization in cancer: structural insights and therapeutic strategies beyond monomer inhibition
    Jayhind Bharti, Priyadharshini Gogu, Dhanashree N. Sarwan, Manish Kumar Pathak, Prem Shankar Gupta, Ashish Ranjan Dwivedi, Prateek Pathak · 2026 · Biochemical Pharmacology
96. Targeting CDKs in the RNAPII transcription cycle
    Robert P. Fisher, Matthias Geyer · 2026 · Nature Reviews Drug Discovery
97. Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption
    Yoko Yoshikawa, Hirokazu Kubota, Shigeyuki Matsumoto, Yoshiteru Makino, Takashi Kawamura, Hitomi Yuki, Naoki Sakai, Akira Shibaike, Megumi Okamura, Wakako Fujimoto-Sakisaka et al. · 2026 · Nature Communications
98. Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition
    Ana Orive-Ramos, Bijaya Gaire, Christos Adamopoulos, Beau Baars, Mathieu Desaunay, Ziyue Kou, Evangelia Matenoglou, Sílvia Coma, Nayeli Gutiérrez, Kevin Mohammed et al. · 2026 · Cancer Discovery
99. The Double-Edged Role of Enzyme Inhibition in Oral Anticancer Therapy
    Abdullah A Assiri · 2026 · Pharmaceutics
100. Binding kinetics enable tumor-selective MAPK and growth suppression by a Type 1 RAF Inhibitor
     Mathieu Desaunay, Tara Peters, Evangelia Matenoglou, Beau Baars, Bijaya Gaire, Ana Orive-Ramos, Li Ren, Joseph P. Lyssikatos, Michael Burkard, Dalton Dacus et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)